The effect of smoking cessation on lipid metabolism in patients after coronary artery bypass grafting
DOI:
https://doi.org/10.14739/2310-1210.2025.4.322058Keywords:
coronary artery bypass grafting, lipid metabolism, statins, smoking cessationAbstract
Aim. The study aimed to comparatively assess lipid metabolism in patients with ischemic heart disease (IHD) before and after coronary artery bypass grafting (CABG) and to evaluate the smoking factor and effects of smoking cessation.
Materials and methods. A total of 122 patients with IHD and indications for CABG were examined (101 men, 21 women; mean age 62.4 ± 0.7 years, range 40–83 years). The patients were divided into two groups: Group I (45 patients <60 years) and Group II (77 patients ≥60 years). Within each group, patients were further divided into subgroups based on smoking status: current smokers (Subgroups IA (n = 28, mean age 55.2 ± 0.9) and IIA (n = 18, mean age 65.0 ± 0.8)) and non-smokers (Subgroups IB (n = 17, mean age 55.2 ± 1.3) and IIB (n = 59, mean age 67.1 ± 0.6)). Lipid metabolism parameters were evaluated at two time points: prior to CABG and six months post-surgery. All patients received statin therapy throughout the study period and those identified as smokers ceased smoking prior to undergoing CABG.
Results. Among smokers (Subgroups IA and IIA), mean levels of proatherogenic lipids were 1.2 to 1.5 times higher, and HDL-C levels were markedly reduced, compared to non-smokers (Subgroups IB and IIB). At 6 months post-CABG, a more pronounced positive change in the lipid profile was observed in Subgroups IA and IIA: LDL-C levels decreased by 47.3 % and 40.7 %, respectively; non-HDL-C by 28.2 % and 24.1 %; and TG by 44.7 % and 29.3 %. In non-smokers, the improvement was less pronounced. At baseline, the proportion of individuals achieving target lipid levels was significantly lower among smokers, regardless of age (p < 0.05): LDL-C <1.4 mmol/L was observed in 46.4 % of Subgroup IA patients compared to 70.6 % in Subgroup IB patients; TG <1.7 mmol/L was achieved by 10.7 % of patients in IA compared to 23.5 % in IB. No individuals in Subgroup IA had target HDL-C or non-HDL-C levels at baseline, whereas these proportions were 29.4 % and 17.7 % in Subgroup IB, respectively. After 6 months, target levels for LDL-C, TG (IA, IIA), and non-HDL-C (IIA) were achieved by 90–100 % of patients (p < 0.05), while the changes in Subgroups IB and IIB were less pronounced.
Conclusions. Among patients with indications for CABG, baseline analysis revealed significantly elevated mean levels of proatherogenic lipids and low HDL-C levels among smokers, as well as the highest proportion of patients failing to achieve target lipid levels, despite prior statin therapy. The most pronounced improvement in lipid metabolism at 6 months was documented among the patients who ceased smoking. These findings suggest that smoking cessation enhances the hypolipidemic effect of statin therapy.
References
Bachar BJ, Manna B. Coronary Artery Bypass Graft. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507836/
Mitchenko OI, Lutai MI. Rekomendatsii z diahnostyky ta likuvannia dyslipidemii [Recommendations for the diagnosis and treatment of dyslipidemias]. Kyiv; 2020. Ukrainian. Available from: https://cardiocongress.org.ua/wp-content/uploads/2020/09/Egis_All_Recomendations_A5_48p.pdf
Ishida M, Sakai C, Kobayashi Y, Ishida T. Cigarette Smoking and Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb. 2024;31(3):189-200. doi: https://doi.org/10.5551/jat.RV22015
Moradinazar M, Pasdar Y, Najafi F, Shahsavari S, Shakiba E, Hamzeh B, et al. Association between dyslipidemia and blood lipids concentration with smoking habits in the Kurdish population of Iran. BMC Public Health. 2020;20(1):673. doi: https://doi.org/10.1186/s12889-020-08809-z
Mallah MA, Soomro T, Ali M, Noreen S, Khatoon N, Kafle A, et al. Cigarette smoking and air pollution exposure and their effects on cardiovascular diseases. Front Public Health. 2023;11:967047. doi: https://doi.org/10.3389/fpubh.2023.967047
Hlobalne opytuvannia doroslykh shchodo vzhyvannia tiutiunu (Global Adult Tobacco Survey – GATS). Kyiv; 2017. Ukrainian. Available from: https://kiis.com.ua/materials/pr/20180214_GATS/Full%20Report%20GATS%20Ukraine%202017%20UKR.pdf
Kvasha OO, Sirenko YM, Horbas IM, Vavilova LL. Vidmova vid tiutiunokurinnia u patsiientiv iz sertsevo-sudynnymy zakhvoriuvanniamy (Metodychni rekomendatsii dlia likariv, 2014) [Smoking cessation in patients with cardiovascular diseases (Guidelines for physicians, 2014)]. Novyny medytsyny ta farmatsii. 2014;(13-14):18-20. Ukrainian. Available from: http://www.mif-ua.com/archive/article/39014
Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e18-e114. doi: https://doi.org/10.1161/CIR.0000000000001038. Erratum in: Circulation. 2022;145(11):e772. doi: https://doi.org/10.1161/CIR.0000000000001060
Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-537. doi: https://doi.org/10.1093/eurheartj/ehae177. Erratum in: Eur Heart J. 2025;46(16):1565. doi: https://doi.org/10.1093/eurheartj/ehaf079
European Society of Cardiology. 2024 ESC Guidelines for the management of chronic coronary syndromes [Internet]. Escardio.org. 2024 [cited 2025 Jun 8]. Available from: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Chronic-Coronary-Syndromes
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi: https://doi.org/10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020;41(44):4255. doi: https://doi.org/10.1093/eurheartj/ehz826
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi: https://doi.org/10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022;43(42):4468. doi: https://doi.org/10.1093/eurheartj/ehac458
Choudhary A, Rawat U, Kumar P, Mittal P. Pleotropic effects of statins: the dilemma of wider utilization of statin. Egypt Heart J. 2023;75(1):1. doi: https://doi.org/10.1186/s43044-023-00327-8
Ursoniu S, Mikhailidis DP, Serban MC, Penson P, Toth PP, Ridker PM, et al. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2017;122:105-17. doi: https://doi.org/10.1016/j.phrs.2017.06.002
Korhonen MJ, Pentti J, Hartikainen J, Ilomäki J, Setoguchi S, Liew D, et al. Lifestyle Changes in Relation to Initiation of Antihypertensive and Lipid-Lowering Medication: A Cohort Study. J Am Heart Assoc. 2020;9(4):e014168. doi: https://doi.org/10.1161/JAHA.119.014168
Ministry of Health of Ukraine. [Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care "Stable coronary heart disease"]. Order dated 2016 Mar 2, No. 152. Ukrainian. Available from: http://mtd.dec.gov.ua/images/dodatki/2016_152_IHS/2016_152_YKPMD_IHS.pdf
Balsara K, Iftikhar A, Galiatsatos P, DiClemente C, Mattingly B, Kanarek NF. Cigarette Smoking, Mental Health, Depression, Maryland Behavioral Risk Factor Surveillance System Survey, 2020. Tob Use Insights. 2024;17:1179173X241285351. doi: https://doi.org/10.1177/1179173X241285351
Yuan X, Du J, Liu Q, Zhang L. Defining the role of perioperative statin treatment in patients after cardiac surgery: A meta-analysis and systematic review of 20 randomized controlled trials. Int J Cardiol. 2017;228:958-66. doi: https://doi.org/10.1016/j.ijcard.2016.11.116
Curtis M, Deng Y, Lee VV, Elayda MA, Coselli JS, Collard CD, et al. Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery. Ann Thorac Surg. 2017;104(3):782-9. doi: https://doi.org/10.1016/j.athoracsur.2016.12.043
Galyfos G, Sianou A, Filis K. Pleiotropic effects of statins in the perioperative setting. Ann Card Anaesth. 2017;20(Supplement):S43-8. doi: https://doi.org/10.4103/0971-9784.197796
Zhang C, Zhang C. Perioperative statin reloading in cardiac surgery: A review. Heart and Circulatory System. 2020;1-6. doi: https://doi.org/10.31487/j.hcs.2020.01.01
Athyros VG, Tziomalos K, Katsiki N, Gossios TD, Giouleme O, Anagnostis P, et al. The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol. 2013;11(5):779-84. doi: https://doi.org/10.2174/1570161111311050016
Chen L-F, Li S-C, Yang C, Zhang Y, Feng C, Wu W-L, et al. Cigarette smoking-induced low-density lipoprotein ( LDL ) dysfunction is partially reversible after smoking cessation. Int J Clin Exp Med. 2018;11(11):11732-42. Available from: https://e-century.us/files/ijcem/11/11/ijcem0079079.pdf
Zhang X, Peng X, Li L, Yu H, Yu B. Persistent Cigarette Smoking Attenuates Plaque Stabilization in Response to Lipid-Lowering Therapy: A Serial Optical Coherence Tomography Study. Front Cardiovasc Med. 2021;8:616568. doi: https://doi.org/10.3389/fcvm.2021.616568
Lin MJ, Lin HD, Cai CZ, Chuang MJ, Yang FC, Chiang KF, Wu HP. Effect of statin on long-term outcomes in persistent tobacco users receiving percutaneous coronary intervention: A longitudinal, retrospective cohort study. Medicine (Baltimore). 2024;103(45):e40463. doi: https://doi.org/10.1097/MD.0000000000040463
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 I. M. Bihun, T. M. Solomenchuk

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.